The market is driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness
1h Free Analyst Time
The dementia and movement disorder treatment market is forecasted to grow by USD 8.55 bn during 2023-2028, accelerating at a CAGR of 7.28% during the forecast period. The report on the dementia and movement disorder treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing geriatric population, rising prevalence of target diseases, and emergence of strategies to increase public awareness.
The dementia and movement disorder treatment market is segmented as below:
By Application
- Movement disorders
- Progressive dementia
- Progressive dementia with neurological abnormality (PDNA)
By Drug Class
- MAO inhibitors
- Acetylcholinesterase inhibitors
- Glutamate inhibitors
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the dementia and movement disorder treatment market covers the following areas:
- Dementia and movement disorder treatment market sizing
- Dementia and movement disorder treatment market forecast
- Dementia and movement disorder treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Drug Class
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global dementia and movement disorder treatment market: AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA.Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is emergence of biomarkers.'
According to the report, one of the major drivers for this market is the growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Biogen Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline Plc
- H Lundbeck AS
- Johnson and Johnson
- Kirin Holdings Co. Ltd.
- Lannett Co. Inc.
- Merck and Co. Inc.
- Neurocrine Biosciences Inc.
- Novartis AG
- Organon and Co.
- Orion Pharma Ltd.
- Otsuka Holdings Co. Ltd.
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
